You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥與大塚製藥達成全球戰略合作,共同推進BCMAxCD3雙特異性T細胞銜接器開發
和鉑醫藥(2142.HK)宣佈與大塚製藥株式會社(以下簡稱“大塚製藥”)達成全球戰略合作,雙方將共同推進用於治療自身免疫性疾病的BCMAxCD3雙特異性T細胞銜接器的開發。 根據協議條款,大塚製藥將獲得在全球範圍內(不包括大中華區,即中國大陸、中國香港、中國澳門和中國臺灣)開發、生產和商業化HBM7020(一款BCMAxCD3雙特異性T細胞銜接器)的獨家許可。和鉑醫藥將獲得總計4700萬美元的首付款和近期里程碑付款。此外,在達成特定研發和商業里程碑後,和鉑醫藥還有權獲得高達6.23億美元的額外付款,以及基於未來產品淨銷售額的分級特許權使用費。在此次戰略合作的基礎上,雙方將探討未來在T細胞銜接器領域進一步合作的機會。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account